Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative)
This article is a report of the fourth meeting of the Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23-24 April 2015 (HOME IV). The aim of the meeting was to achieve consensus over the preferred outcome instruments for measuring patient-reported symptoms and quality of life for the HOME core outcome set for atopic eczema (AE). Following presentations, which included data from systematic reviews, consensus discussions were held in a mixture of whole group and small group discussions. Small groups were allocated a priori to ensure representation of different stakeholders and countries. Decisions were voted on using electronic keypads. For the patient-reported symptoms, the group agreed by vote that itch, sleep loss, dryness, redness/inflamed skin and irritated skin were all considered essential aspects of AE symptoms. Many instruments for capturing patient-reported symptoms were discussed [including the Patient-Oriented SCOring Atopic Dermatitis index, Patient-Oriented Eczema Measure (POEM), Self-Administered Eczema Area and Severity Index, Itch Severity Scale, Atopic Dermatitis Quickscore and the Nottingham Eczema Severity Score] and, by consensus, POEM was selected as the preferred instrument to measure patient-reported symptoms. Further work is needed to determine the reliability and measurement error of POEM. Further work is also required to establish the importance of pain/soreness and the importance of collecting information regarding the intensity of symptoms in addition to their frequency. Much of the discussion on quality of life concerned the Dermatology Life Quality Index and Quality of Life Index for Atopic Dermatitis; however, consensus on a preferred instrument for measuring this domain could not be reached. In summary, POEM is recommended as the HOME core outcome instrument for measuring AE symptoms.
Checklist, Clinical Trials as Topic, Dermatitis, Atopic/therapy, Dermatologic Agents/therapeutic use, Global Health, Humans, Long-Term Care, Patient Reported Outcome Measures, Quality of Life, Review Literature as Topic, Treatment Outcome
69-79
Chalmers, J.R.
94e08e98-5c93-405d-9278-97acfe4985a0
Simpson, E.
127514a1-9431-48d2-b3dc-ff871a5e4155
Apfelbacher, C.J.
cf3552c6-92ea-4f3d-8150-9f19c922f590
Thomas, K.S.
cd26bdad-69c4-434a-9ccb-d3efa945a3d3
von Kobyletzki, L.
8fbbf78b-e2e2-4ad7-ad3f-29d313521873
Schmitt, J.
ec95552c-6f07-4549-8582-86933b3c6599
Singh, J.A.
26e60da2-de4c-44d1-9020-b55aeaefa91e
Svensson, Å.
703d7057-ebf6-4002-85b9-dd6392a3c59d
Williams, H.C.
feacc6df-79cb-41cf-a947-9d5cce22011c
Abuabara, K.
10a2192f-d7fb-4ef8-90d4-b58cc0aa9c7c
Aoki, V.
cc60023d-d343-4c9d-9dab-ff8a8806ada8
Ardeleanu, M.
ee060a44-0227-47bb-9a8e-adfe4a8cc477
Awici-Rasmussen, M.
0114cfb9-57ee-4150-84c0-888cc06cd6eb
Barbarot, S.
6ddfb8ad-9f41-4ba5-a1af-ff247981f4f2
Berents, T.L.
4d5592ee-c8f5-4034-b765-0391bbef5eb4
Block, J.
df6c154d-7166-4a39-beb3-a962249a75c6
Bragg, A.
0083c184-46ec-403b-995f-7054671828e3
Burton, T.
84cc8f88-8b62-4223-8050-bdfc65611d5e
Bjerring Clemmensen, K.K.
889992b5-7751-4433-8f5c-8714f16a2463
Creswell-Melville, A.
2c9daeb7-94c0-4db9-adf2-a0bf69d36c6e
Dinesen, M.
5ec171a1-2404-4a3d-bf43-cb46ddc2a97d
Drucker, A.
1c94c0a7-c14b-44c2-a1d6-62f6a0ee0e0c
Eckert, L.
b2f0cad4-7e41-4327-9514-bf6ca59a9b39
Flohr, C.
2cd7a518-1a24-4fc7-b099-2a032fdf2068
Garg, M.
be328e0d-f0d6-4059-a5bd-d1a7e62e0867
Gerbens, L.A.A.
e6800106-6232-44f1-ab9d-b1e7e6ad66d9
Graff, A.L.B.
8b883bef-52af-46e4-b46f-3db1108af7ff
Hanifin, J.
a9c2b138-4c0d-4aa0-b966-99a4b8cc51d4
Heinl, D.
29c88699-32d3-4045-8000-ae3652c0c8fa
Humphreys, R.
ba7acc08-ed16-4315-ac5b-31c67e3d0e5c
Ishii, H.A.
9f815fe9-a09e-4ab9-a74b-b965fe85ed83
Kataoka, Y.
0d8cb2b8-0dea-45e5-9b2f-e813bfc1a41c
Leshem, Y.A.
2b93efc1-acd0-4275-835c-7e42eb90a4c7
Marquort, B.
d0a1010a-4bb6-4735-baac-78dbf11da3d5
Massuel, M.-A.
9bdfae78-75a2-4ba6-9bb0-ec44b4fa9eca
Merhand, S.
72db0d60-48bd-482b-8893-5eb4437c9c64
Mizutani, H.
654eb32d-b191-43ac-9e43-92e6e1b9948e
Murota, H.
0bdbddc6-c373-42fb-9c35-911f7979e477
Murrell, D.F.
62da494e-e6f0-4abd-893a-538ba3e612b8
Nakahara, T.
f19d5235-0589-4f90-bca0-59dd486a5679
Nasr, I.
dbb9b1b2-ba7c-417d-b048-1d16b1a09a85
Nograles, K.
e6d7c193-0214-42a8-a73f-548f5603f509
Ohya, Y.
4ad7d24a-4ae4-4320-a658-56d645b8365d
Osterloh, I.
6df28def-5263-46cf-8f20-528f950bb8f0
Pander, J.
4241f3f3-af6b-4105-a213-7f84cd1ab57c
Prinsen, C.
f30459a0-1a60-42f8-98e9-b782c3fbce15
Purkins, L.
67c5d676-11f7-46ec-af95-9fdf5a8aa308
Ridd, M.
2f15120c-d5fa-4f5d-bb86-21356e034df7
Sach, T.
5c09256f-ebed-4d14-853a-181f6c92d6f2
Zhao, C.Y.
b09dbfd0-1e25-4821-a713-842c64fff508
on behalf of the long-term control of eczema working group for the HOME initiative
1 July 2016
Chalmers, J.R.
94e08e98-5c93-405d-9278-97acfe4985a0
Simpson, E.
127514a1-9431-48d2-b3dc-ff871a5e4155
Apfelbacher, C.J.
cf3552c6-92ea-4f3d-8150-9f19c922f590
Thomas, K.S.
cd26bdad-69c4-434a-9ccb-d3efa945a3d3
von Kobyletzki, L.
8fbbf78b-e2e2-4ad7-ad3f-29d313521873
Schmitt, J.
ec95552c-6f07-4549-8582-86933b3c6599
Singh, J.A.
26e60da2-de4c-44d1-9020-b55aeaefa91e
Svensson, Å.
703d7057-ebf6-4002-85b9-dd6392a3c59d
Williams, H.C.
feacc6df-79cb-41cf-a947-9d5cce22011c
Abuabara, K.
10a2192f-d7fb-4ef8-90d4-b58cc0aa9c7c
Aoki, V.
cc60023d-d343-4c9d-9dab-ff8a8806ada8
Ardeleanu, M.
ee060a44-0227-47bb-9a8e-adfe4a8cc477
Awici-Rasmussen, M.
0114cfb9-57ee-4150-84c0-888cc06cd6eb
Barbarot, S.
6ddfb8ad-9f41-4ba5-a1af-ff247981f4f2
Berents, T.L.
4d5592ee-c8f5-4034-b765-0391bbef5eb4
Block, J.
df6c154d-7166-4a39-beb3-a962249a75c6
Bragg, A.
0083c184-46ec-403b-995f-7054671828e3
Burton, T.
84cc8f88-8b62-4223-8050-bdfc65611d5e
Bjerring Clemmensen, K.K.
889992b5-7751-4433-8f5c-8714f16a2463
Creswell-Melville, A.
2c9daeb7-94c0-4db9-adf2-a0bf69d36c6e
Dinesen, M.
5ec171a1-2404-4a3d-bf43-cb46ddc2a97d
Drucker, A.
1c94c0a7-c14b-44c2-a1d6-62f6a0ee0e0c
Eckert, L.
b2f0cad4-7e41-4327-9514-bf6ca59a9b39
Flohr, C.
2cd7a518-1a24-4fc7-b099-2a032fdf2068
Garg, M.
be328e0d-f0d6-4059-a5bd-d1a7e62e0867
Gerbens, L.A.A.
e6800106-6232-44f1-ab9d-b1e7e6ad66d9
Graff, A.L.B.
8b883bef-52af-46e4-b46f-3db1108af7ff
Hanifin, J.
a9c2b138-4c0d-4aa0-b966-99a4b8cc51d4
Heinl, D.
29c88699-32d3-4045-8000-ae3652c0c8fa
Humphreys, R.
ba7acc08-ed16-4315-ac5b-31c67e3d0e5c
Ishii, H.A.
9f815fe9-a09e-4ab9-a74b-b965fe85ed83
Kataoka, Y.
0d8cb2b8-0dea-45e5-9b2f-e813bfc1a41c
Leshem, Y.A.
2b93efc1-acd0-4275-835c-7e42eb90a4c7
Marquort, B.
d0a1010a-4bb6-4735-baac-78dbf11da3d5
Massuel, M.-A.
9bdfae78-75a2-4ba6-9bb0-ec44b4fa9eca
Merhand, S.
72db0d60-48bd-482b-8893-5eb4437c9c64
Mizutani, H.
654eb32d-b191-43ac-9e43-92e6e1b9948e
Murota, H.
0bdbddc6-c373-42fb-9c35-911f7979e477
Murrell, D.F.
62da494e-e6f0-4abd-893a-538ba3e612b8
Nakahara, T.
f19d5235-0589-4f90-bca0-59dd486a5679
Nasr, I.
dbb9b1b2-ba7c-417d-b048-1d16b1a09a85
Nograles, K.
e6d7c193-0214-42a8-a73f-548f5603f509
Ohya, Y.
4ad7d24a-4ae4-4320-a658-56d645b8365d
Osterloh, I.
6df28def-5263-46cf-8f20-528f950bb8f0
Pander, J.
4241f3f3-af6b-4105-a213-7f84cd1ab57c
Prinsen, C.
f30459a0-1a60-42f8-98e9-b782c3fbce15
Purkins, L.
67c5d676-11f7-46ec-af95-9fdf5a8aa308
Ridd, M.
2f15120c-d5fa-4f5d-bb86-21356e034df7
Sach, T.
5c09256f-ebed-4d14-853a-181f6c92d6f2
Zhao, C.Y.
b09dbfd0-1e25-4821-a713-842c64fff508